Press release
Investigation announced for Investors in shares of Vaccinex, Inc. (NASDAQ: VCNX)
An investigation for investors in Vaccinex, Inc. (NASDAQ: VCNX) shares over potential securities laws violations by Vaccinex, Inc.
Investors who purchased shares of Vaccinex, Inc. (NASDAQ: VCNX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Vaccinex, Inc. (NASDAQ: VCNX) concerning whether a series of statements by Vaccinex, Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Rochester, NY based Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. On August 9, 2018, Vaccinex, Inc. announced the pricing for its initial public offering. Vaccinex, Inc sold 3.33 million shares at $12.00 per share. Since then shares of Vaccinex, Inc. (NASDAQ: VCNX) declined to as low as $3.94 per share on July 26, 2019.
Those who purchased shares of Vaccinex, Inc. (NASDAQ: VCNX) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Vaccinex, Inc. (NASDAQ: VCNX) here
News-ID: 1824099 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Vaccinex
Global DISPLAY LIBRARY TECHNOLOGIES AND AFFILIATED SERVICES Market Analysis 2016 …
DISPLAY LIBRARY TECHNOLOGIES AND AFFILIATED SERVICES Market research report is the new statistical data source added by Infinity Business Insights.
Display libraries have been successfully used in modern medical research to develop a variety of novel therapeutics, and they have several advantages over traditional drug screening methods, including the ability to conduct large-scale, high-throughput screening, the incorporation of greater diversity in viable lead identification, and the elimination of the risk…
Investigation announced for Long-Term Investors in shares of Vaccinex, Inc. (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain officers and directors at Vaccinex, Inc..
Investors who purchased shares of Vaccinex, Inc. (NASDAQ: VCNX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vaccinex, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Rochester, NY based Vaccinex,…
Antibody Drug Conjugate Market Grows at 19% of CAGR with Seattle Genetics, Immun …
The Global Antibody Drug Conjugate Market is rising with a swift phase; mainly owing to increase in patient population suffering with cancer. This therapy have ability to treat different type of cancer such as endometrial and breast cancer. According to WHO, in 2015, around 570,000 women died owing to breast cancer globally, which are approximately 15% of all cancer deaths among women. Breast cancer is most frequent cancer among the…
Global Antibody Library Technologies Market will Garner US$ 172.9 Mn in Revenues …
Demand for antibody library technologies is expected to surge, as the arrival of advanced antibodies and their display technologies continue to reduce complexities of life science and biotechnology research. Persistence Market Research (PMR), in its latest report, projects that the global antibody library technologies market revenue will increase at a CAGR of 4.4% between 2016 and 2024. Some of the latest antibody library design and selection methods enable easy…
Global Vasculitis Treatment Market Will Hit At CAGR Of 4.20 % During Years 2017- …
Latest industry research report on: Global Vasculitis Treatment Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Download Sample copy of this Report at :https://www.marketresearchreports.biz/sample/sample/1180512
Vasculitis is an autoimmune disorder that causes inflammation of the blood vessels. The body's immune system attacks the blood vessels, which results in inflammation. When this inflammation occurs, the walls of the affected blood vessels get thicker and the passages through which…
Asia Pacific and Middle East to lead Epidermal Growth Factor Receptor (EGFR) Ant …
EGFR is the primary receptor recognized in a group of receptors and is a cell surface protein that binds to epidermal growth factor. EGFR is a cell membrane growth factor receptor characterized by tyrosine kinase receptor which plays very important role in the control of key cellular transduction pathways in both normal and cancerous cells. EGFR is the first molecular target against which monoclonal antibodies (mAb) have been developed in…
